Miracle Mile Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Miracle Mile Advisors’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.43M	Sell	111,561 -257	-0.2%	-$14.8K	0.08%	181
2026 Q1	$6.78M	Sell	111,818 -60	-0.1%	-$3.5K	0.09%	156
2025 Q4	$6.03M	Buy	111,878 +513	+0.5%	+$24.7K	0.09%	166
2025 Q3	$5.02M	Sell	111,365 -1,955	-2%	-$91.3K	0.08%	182
2025 Q2	$5.25M	Buy	113,320 +799	+0.7%	+$39.2K	0.09%	150
2025 Q1	$6.86M	Sell	112,521 -1,524	-1%	-$88.8K	0.14%	107
2024 Q4	$6.45M	Buy	114,045 +7,109	+7%	+$397K	0.13%	114
2024 Q3	$5.53M	Sell	106,936 -613	-0.6%	-$28.8K	0.13%	106
2024 Q2	$4.47M	Buy	107,549 +10,749	+11%	+$481K	0.11%	117
2024 Q1	$5.25M	Buy	96,800 +89,568	+1,238%	+$4.56M	0.13%	109
2023 Q4	$371K	Sell	7,232 -846	-10%	-$44.4K	0.01%	368
2023 Q3	$469K	Sell	8,078 -299	-4%	-$18.3K	0.01%	333
2023 Q2	$536K	Buy	8,377 +799	+11%	+$53.6K	0.02%	340
2023 Q1	$525K	Sell	7,578 -796	-10%	-$56.1K	0.02%	351
2022 Q4	$602K	Sell	8,374 -1,968	-19%	-$148K	0.02%	328
2022 Q3	$735K	Sell	10,342 -9,503	-48%	-$689K	0.03%	239
2022 Q2	$1.53M	Buy	19,845 +6,359	+47%	+$484K	0.07%	174
2022 Q1	$985K	Buy	13,486 +9,081	+206%	+$610K	0.04%	237
2021 Q4	$275K	Sell	4,405 -209	-5%	-$12.3K	0.01%	384
2021 Q3	$273K	Buy	4,614 +628	+16%	+$41.4K	0.01%	371
2021 Q2	$266K	Buy	3,986 +373	+10%	+$24.3K	0.01%	329
2021 Q1	$228K	Sell	3,613 -1,533	-30%	-$95.4K	0.01%	344
2020 Q4	$319K	Sell	5,146 -280	-5%	-$17.2K	0.02%	302
2020 Q3	$327K	Sell	5,426 -532	-9%	-$32K	0.02%	279
2020 Q2	$350K	Sell	5,958 -5,911	-50%	-$354K	0.03%	251
2020 Q1	$662K	Buy	+11,869	New	+$725K	0.07%	160
2019 Q2	–	Sell	-33,000	Closed	-$1.57M	–	261
2019 Q1	$1.57M	Buy	+33,000	New	+$1.64M	0.13%	132
2017 Q1	–	Sell	-13,747	Closed	-$803K	–	84
2016 Q4	$803K	Sell	13,747 -3,933	-22%	-$215K	0.19%	35
2016 Q3	$953K	Buy	+17,680	New	+$1.14M	0.24%	28

Other funds holding BMY

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

FWIA

Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

DLA

Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

ETC

Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Miracle Mile Advisors's BMY Position: Q2 2026 in Review

Miracle Mile Advisors reduced its Bristol-Myers Squibb (BMY) stake by 0.23% in Q2 2026, selling an estimated $14.8K and leaving 111,561 shares worth $6.43M. The position accounts for 0.08% of the portfolio, ranked #181.

Miracle Mile Advisors first reported a position in BMY in Q3 2016 and has held it in 29 quarters since. The position peaked at $6.86M in Q1 2025. 832 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Miracle Mile Advisors held 111,561 shares of Bristol-Myers Squibb worth $6.43M as of Q2 2026.
Miracle Mile Advisors sold 257 Bristol-Myers Squibb shares in Q2 2026, an estimated $14.8K.
Bristol-Myers Squibb made up 0.08% of Miracle Mile Advisors's portfolio in Q2 2026, its #181 holding.
Miracle Mile Advisors first reported a position in Bristol-Myers Squibb in Q3 2016 and has held it in 29 quarters since.
Miracle Mile Advisors's Bristol-Myers Squibb position peaked at $6.86M in Q1 2025.
832 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Miracle Mile Advisors's 13F filing for Q2 2026, filed 22 Jul 2026.